1. DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease. (16th January 2018) Authors: Bor, R; Klaudia, F; Miheller, P; Palatka, K; Szamosi, T; Vincze, Á; Rutka, M; Szántó, K; Bálint, A; Szepes, Z; Nagy, F; Milassin, Á; Fábián, A; Csontos, Á; Golovics, P; Lakner, L; Müllner, K; Papp, M; Salamon, Á; Sarang, K Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey. (30th January 2023) Authors: Bikar, A; Farkas, N; Resál, T; Szepes, Z; Klaudia, F; Vincze, Á; Miheller, P; Molnár, T; Sarlós, P Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗